Showing results (41-50 of 70) with videos related to
Sort By:
Pageof 7
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 18, 2024
Squamoid Eccrine Ductal Carcinoma Displays Ultraviolet Mutations and Intermediate Gene Expression Relative to Squamous Cell Carcinoma, Microcystic Adnexal Carcinoma, and PorocarcinomaPaul W Harms, Mason Runge, May P Chan, et al.Head & Neck|January 22, 2016
ACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and NeckShlomo A Koyfman, Jay S Cooper, Jonathan J Beitler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.Head & Neck|December 30, 2016
ACR appropriateness criteria® nasal cavity and paranasal sinus cancersFarzan Siddiqui, Richard V Smith, Sue S Yom, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404)Alan L Ho, Nathan R Foster, Alex J Zoroufy, et al.Cancer|June 28, 2019
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert Haddad, Fernando Concha-Benavente, George Blumenschein, et al.The Lancet. Oncology|March 22, 2015
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 studyMartin Fassnacht, Alfredo Berruti, Eric Baudin, et al.Nature Communications|March 20, 2026
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trialAlexander T Pearson, Jameel Muzaffar, Kedar Kirtane, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2026
Systemic Treatment of Thyroid Cancer: ASCO GuidelineNabil F Saba, Nofisat Ismaila, Douglas Adkins, et al.Pageof 7